Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859084 | 1.00 | PSMB1 (0.52) | PSMB1MMEPSMB5ANPEPCTSL | |
| SCHEMBL20474450 | 1.00 | PSMB1 (0.52) | PSMB1MMEPSMB5ANPEPCTSL | |
| SCHEMBL20474483 | 0.90 | CTSL (0.60) | PSMB1MMEPSMB5CTSLBACE1 | |
| SCHEMBL20474485 | 0.90 | CTSL (0.60) | PSMB1MMEPSMB5CTSLBACE1 | |
| SCHEMBL3837915 | 0.89 | PSMB1 (0.50) | PSMB1ANPEPCTSLREN | |
| SCHEMBL20474448 | 0.87 | ANPEP (0.47) | PSMB1MMEPSMB5ANPEPREN | |
| SCHEMBL17595899 | 0.87 | ANPEP (0.47) | PSMB1MMEPSMB5ANPEPREN | |
| SCHEMBL17596483 | 0.86 | LAP3 (0.46) | MMEANPEP | |
| SCHEMBL17595915 | 0.86 | LAP3 (0.46) | MMEANPEP | |
| SCHEMBL20834865 | 0.86 | REN (0.58) | PSMB1RENBACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L | 2019-09-05 | — | — | US | disclosed |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | LANDSTEINER GENMED, S.L. (ES) | 2019-05-21 | — | — | US | disclosed |
| EP-3191112-B1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L (ES) | 2019-03-20 | — | — | EP | disclosed |
| US-20180237473-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED, S.L. (ES) | 2018-08-23 | — | — | US | disclosed |
| CN-103282043-B | Congenital agyria therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2015-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237473-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | DPP4, DPP3, DPP8 | PSMB1 2859/4885MME 177/4885PSMB5 2009/4885 |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | DPP4, DPP3, DPP8 | PSMB1 2859/4885MME 177/4885PSMB5 2009/4885 |
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | DPP4, DPP3, DPP8 | PSMB1 2859/4885MME 177/4885PSMB5 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.